Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M746Revenue $M47.1Net Margin (%)-6.2Z-Score2.9
Enterprise Value $M367EPS $-2.6Operating Margin %-1.2F-Score5
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-6.2Higher ROA y-yY
Price/Book3.010-y EBITDA Growth Rate %0Quick Ratio6.7Cash flow > EarningsY
Price/Sales4.75-y EBITDA Growth Rate %17.7Current Ratio6.7Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-4.0Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-5.1Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M48.8ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with INFI

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
INFIJohn Burbank 2014-06-30 Sold Out -0.01%$8.6 - $12.67
($10.38)
$ 15.2947%Sold Out0
INFIJohn Burbank 2014-03-31 Buy 0.01%$11.37 - $16.52
($13.45)
$ 15.2914%New holding, 16556 sh.16,556
INFIGeorge Soros 2013-06-30 Sold Out -0.02%$16.192 - $50.09
($30.95)
$ 15.29-51%Sold Out0
INFIGeorge Soros 2013-03-31 Reduce-0.01%$32.93 - $49.37
($39.51)
$ 15.29-61%Reduce -46.67%40,000
INFIGeorge Soros 2012-12-31 Buy 0.03%$17.74 - $35.04
($25.26)
$ 15.29-40%New holding, 75000 sh.75,000
INFIJean-Marie Eveillard 2012-06-30 Sold Out -0.01%$11.71 - $13.76
($12.78)
$ 15.2920%Sold Out0
INFIJean-Marie Eveillard 2012-03-31 Reduce-0.01%$5.9781 - $12.16
($7.96)
$ 15.2992%Reduce -54.94%180,000
INFIJean-Marie Eveillard 2011-09-30 Reduce-0.01%$6.17 - $10.36
($7.87)
$ 15.2994%Reduce -25.85%464,241
INFIWilbur Ross 2011-06-30 Sold Out $5.61 - $8.19
($6.53)
$ 15.29134%Sold Out0
INFIJean-Marie Eveillard 2010-12-31 Add0.01%$5.12 - $6.86
($6.13)
$ 15.29149%Add 60.34%585,437
INFIWilbur Ross 2010-12-31 Reduce-0.02%$5.12 - $6.86
($6.13)
$ 15.29149%Reduce -63.91%7,415
INFIJean-Marie Eveillard 2010-09-30 Add$4.62 - $6.3
($5.51)
$ 15.29178%Add 29.72%365,123
INFIWilbur Ross 2010-09-30 Reduce-0.01%$4.62 - $6.3
($5.51)
$ 15.29178%Reduce -25.39%20,545
INFIJean-Marie Eveillard 2010-06-30 Add0.01%$5.88 - $7.94
($6.59)
$ 15.29132%Add 566.95%281,460
INFIJean-Marie Eveillard 2009-12-31 Add$5.5 - $6.57
($5.92)
$ 15.29158%Add 451.43%42,201
INFIJean-Marie Eveillard 2009-09-30 Buy $5.42 - $8.8
($6.97)
$ 15.29119%New holding, 7653 sh.7,653
INFIWilbur Ross 2009-03-31 Buy 0.12%$7.1 - $8.28
($7.9)
$ 15.2994%New holding, 28437 sh.28,437
INFIJean-Marie Eveillard 2008-12-31 Buy $4.73 - $8.05
($6.3)
$ 15.29143%New holding, 28100 sh.28,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

INFI is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


INFI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Palombella Vito J.Chief Scientific Officer 2014-12-15Sell4,737$16.32-6.31view
Palombella Vito J.Chief Scientific Officer 2014-11-26Sell4,736$151.93view
EVNIN ANTHONY BDirector 2014-09-30Sell112,451$13.5612.76view
Palombella Vito J.Chief Scientific Officer 2014-09-03Sell9,472$15.39-0.65view
Palombella Vito J.Chief Scientific Officer 2014-07-01Sell879$12.8718.8view
Palombella Vito J.Chief Scientific Officer 2014-02-25Sell4,736$151.93view
Palombella Vito J.Chief Scientific Officer 2014-01-02Sell753$13.5213.09view
EVNIN ANTHONY BDirector 2013-12-02Sell17,756$14.565.01view
EVNIN ANTHONY BDirector 2013-11-27Sell163,864$14.823.17view
Palombella Vito J.Chief Scientific Officer 2013-09-27Sell4,736$17.28-11.52view

Press Releases about INFI :

Quarterly/Annual Reports about INFI:

News about INFI:

Articles On GuruFocus.com
comment on INFI Mar 02 2013 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) Aug 04 2010 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) May 06 2010 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) Aug 06 2009 
Infinity Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2009 

More From Other Websites
Infinity Provides Key 2015 Goals and Financial Guidance Jan 14 2015
INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 12 2015
Infinity Provides Key 2015 Goals and Financial Guidance Jan 12 2015
Midday movers: Apple, Ford Motor, Yahoo & more Jan 08 2015
Ahead of the Bell: Infinity Pharmaceuticals shares slide Jan 08 2015
Ahead of the Bell: Infinity Pharmaceuticals shares slide Jan 08 2015
Infinity to stop development of rheumatoid-arthritis treatment Jan 08 2015
Infinity to Stop Development on Rheumatoid Arthritis Treatment Jan 08 2015
INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 08 2015
Infinity Reports Topline Results from Phase 2 Study of Duvelisib in Rheumatoid Arthritis Jan 08 2015
Infinity Reports Topline Results from Phase 2 Study of Duvelisib in Rheumatoid Arthritis Jan 08 2015
Infinity to Present at J.P. Morgan 33rd Annual Healthcare Conference Jan 05 2015
Infinity to Present at J.P. Morgan 33rd Annual Healthcare Conference Jan 05 2015
India Market Lower, Troubling Militant Attacks Dec 23 2014
Disposal of hydro business for £20.5m Dec 19 2014
Form 8.3 - Infinis Energis Plc Dec 19 2014
Lightning Round: I want this to go lower Dec 15 2014
Response to Terra Firma announcement Dec 15 2014
Infinity Reports New Results from Phase 1 Study of Investigational Oncology Compound Duvelisib at... Dec 09 2014
Infinity Reports New Results from Phase 1 Study of Investigational Oncology Compound Duvelisib at... Dec 09 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK